Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Can-Fite BioPharma Ltd.CANF · Entity 8141 | Director | March 18, 2026 | March 18, 2026 |
| Microbot Medical Inc.MBOT · Entity 6767 | Director | November 02, 2023 | November 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Can-Fite BioPharma Ltd.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $241.47 · Expires 2031-06-22 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee. F2: These options are fully vested and exercisable as of the date hereof. F3: The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 750, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. |
| Options to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $25.21 · Expires 2033-04-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee. F4: The exercise price of this option, originally denominated in NIS in the amount of NIS 78.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,489 options are vested, and the remaining 677 options vest in five equal quarterly installments beginning 05/01/2026 and ending 05/01/2027 subject to the Reporting Person's continued service to the Issuer as of such vesting date. |
| Options to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $26.56 · Expires 2034-05-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee. F5: The exercise price of this option, originally denominated in NIS in the amount of NIS 82.5, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 947 options are vested, and the remaining 1,219 options vest in nine equal quarterly installments beginning 05/07/2026 and ending 05/07/2028 subject to the Reporting Person's continued service to the Issuer as of such vesting date. |
| Options to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2030-01-25 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee. F6: The exercise price of this option, originally denominated in NIS in the amount of NIS 6.767, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein, none are vested, and all the 16,000 options vest in sixteen equal quarterly installments beginning 04/25/2026 and ending 01/25/2030 subject to the Reporting Person's continued service to the Issuer as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee.
F2: These options are fully vested and exercisable as of the date hereof.
F3: The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 750, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
F4: The exercise price of this option, originally denominated in NIS in the amount of NIS 78.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,489 options are vested, and the remaining 677 options vest in five equal quarterly installments beginning 05/01/2026 and ending 05/01/2027 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
F5: The exercise price of this option, originally denominated in NIS in the amount of NIS 82.5, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 947 options are vested, and the remaining 1,219 options vest in nine equal quarterly installments beginning 05/07/2026 and ending 05/07/2028 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
F6: The exercise price of this option, originally denominated in NIS in the amount of NIS 6.767, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein, none are vested, and all the 16,000 options vest in sixteen equal quarterly installments beginning 04/25/2026 and ending 01/25/2030 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
Microbot Medical Inc.
Report date November 02, 2023 · Filed November 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.28 · Expires 2033-11-02 | Direct | 74,218 |
Reported balance
After 2023-11-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-11-02 · Grant · Acquired 74,218 · Balance 74,218 F1: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended: (a) on May 2, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended: (a) on May 2, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2023 Filed Nov 6, 2023 21:15 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 74,218 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001493152-23-039531 · ownership.xml · derivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,218 Underlying: Common Stock, par value $0.01 per share · 74,218 shares Expires 2033-11-02 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended: (a) on May 2, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| September 21, 2022 Filed Sep 23, 2022 10:41 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 16,637 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0001493152-22-026614 · ownership.xml · derivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,637 Underlying: Common Stock, par value $0.01 per share · 16,637 shares Expires 2032-09-21 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 21, 2023, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| September 29, 2021 Filed Oct 5, 2021 22:15 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 13,571 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001493152-21-024672 · ownership.xml · derivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,571 Underlying: Common Stock, par value $0.01 per share · 13,571 shares Expires 2031-09-29 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 29, 2022, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 22:15 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 2,771 | $0.00 Strike: $7.22 | $0.00 |
DisclosureSEC source: 0001493152-20-020844 · ownership.xml · derivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,771 Underlying: Common Stock, par value $0.01 per share · 2,771 shares Expires 2030-11-05 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on May 5, 2021, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| October 19, 2020 Filed Oct 21, 2020 21:22 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 4,881 | $7.94 | $38,734.64 |
DisclosureSEC source: 0001493152-20-019762 · ownership.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 242,028 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 4,881 shares of Issuer common stock on October 19, 2020. Accordingly, Reporting Person beneficially owned 242,028 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 12, 2020 Filed Oct 21, 2020 21:25 UTC Amendment | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 20,000 | $7.84 | $156,898.00 |
DisclosureSEC source: 0001493152-20-019763 · ownership.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 246,909 F1 · date: The original Form 4 filed on October 13, 2020 is amended by this Form 4 amendment to correctly reflect the transaction date in Table 1, Item 2. No other changes have been made to the original Form 4. F2 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 20,000 shares of Issuer common stock on October 12, 2020. Accordingly, Reporting Person beneficially owned 246,909 shares of Issuer common stock following the reported transactions. F3 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 20:58 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 5,119 | $7.74 | $39,636.93 |
DisclosureSEC source: 0001493152-20-019036 · ownership.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 266,909 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 20,000 shares of Issuer common stock on October 5, 2020. Accordingly, Reporting Person beneficially owned 266,909 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 20:58 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 14,881 | $7.74 | $115,213.17 |
DisclosureSEC source: 0001493152-20-019036 · ownership.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 272,028 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 20,000 shares of Issuer common stock on October 5, 2020. Accordingly, Reporting Person beneficially owned 266,909 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 05, 2020 Filed Oct 13, 2020 21:00 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 20,000 | $7.84 | $156,898.00 |
DisclosureSEC source: 0001493152-20-019358 · ownership.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 246,909 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 20,000 shares of Issuer common stock on October 12, 2020. Accordingly, Reporting Person beneficially owned 246,909 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:30 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 119 | $11.91 | $1,417.44 |
DisclosureSEC source: 0001493152-20-016316 · ownership.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 286,909 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 15,119 shares of Issuer common stock on August 17, 2020. Accordingly, Reporting Person beneficially owned 286,909 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:30 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 15,000 | $10.18 | $152,676.00 |
DisclosureSEC source: 0001493152-20-016316 · ownership.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 287,028 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 15,119 shares of Issuer common stock on August 17, 2020. Accordingly, Reporting Person beneficially owned 286,909 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 23, 2019 Filed Oct 24, 2019 23:21 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 3,952 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001493152-19-015942 · ownership.xml · derivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,952 Underlying: Common Stock, par value $0.01 per share · 3,952 shares Expires 2029-10-23 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on April 23, 2020, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| January 21, 2019 Filed Jan 23, 2019 22:44 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 2,326 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001493152-19-000864 · ownership.xml · derivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,326 Underlying: Common Stock, par value $0.01 per share · 2,326 shares Expires 2029-01-21 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on March 4, 2019, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 21:49 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 35,000 | $1.06 | $37,191.00 |
DisclosureSEC source: 0001493152-18-000421 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,530,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 35,000 shares of Issuer common stock on January 9, 2018. Accordingly, Reporting Person beneficially owned 4,530,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 18:55 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 2,868 | $1.01 | $2,884.06 |
DisclosureSEC source: 0001493152-18-000142 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,565,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 2,868 shares of Issuer common stock on January 3, 2018. Accordingly, Reporting Person beneficially owned 4,565,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 20:12 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 42,132 | $1.01 | $42,515.40 |
DisclosureSEC source: 0001493152-18-000089 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,568,277 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 42,132 shares of Issuer common stock on January 2, 2018. Accordingly, Reporting Person beneficially owned 4,568,277 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 27, 2017 Filed Dec 28, 2017 18:21 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 14,257 | $1.02 | $14,573.51 |
DisclosureSEC source: 0001493152-17-015176 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,610,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 14,257 shares of Issuer common stock on December 27, 2017. Accordingly, Reporting Person beneficially owned 4,610,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 26, 2017 Filed Dec 27, 2017 21:32 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 30,743 | $1.02 | $31,416.27 |
DisclosureSEC source: 0001493152-17-015110 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,624,666 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 30,743 shares of Issuer common stock on December 26, 2017. Accordingly, Reporting Person beneficially owned 4,624,666 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 22:03 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 12,933 | $1.03 | $13,328.75 |
DisclosureSEC source: 0001493152-17-014953 · form4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,655,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 45,000 shares of Issuer common stock on December 19, 2017 and December 20, 2017. Accordingly, Reporting Person beneficially owned 4,655,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 19, 2017 Filed Dec 21, 2017 22:03 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 32,067 | $1.03 | $33,029.01 |
DisclosureSEC source: 0001493152-17-014953 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,655,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 45,000 shares of Issuer common stock on December 19, 2017 and December 20, 2017. Accordingly, Reporting Person beneficially owned 4,655,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 13, 2017 Filed Dec 14, 2017 17:55 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 841 | $1.02 | $857.82 |
DisclosureSEC source: 0001493152-17-014589 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,700,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 841 shares of Issuer common stock on December 13, 2017. Accordingly, Reporting Person beneficially owned 4,700,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:44 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 44,159 | $1.04 | $45,801.71 |
DisclosureSEC source: 0001493152-17-014564 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,701,250 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 44,159 shares of Issuer common stock on December 12, 2017. Accordingly, Reporting Person beneficially owned 4,701,250 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 06, 2017 Filed Dec 7, 2017 23:22 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 15,375 | $1.05 | $16,157.59 |
DisclosureSEC source: 0001493152-17-014345 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,745,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 15,375 shares of Issuer common stock on December 6, 2017. Accordingly, Reporting Person beneficially owned 4,745,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 22:05 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 38,095 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001493152-17-014419 · form4.xml · derivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,095 Underlying: Common Stock, par value $0.01 per share · 38,095 shares Expires 2027-12-06 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on the six month anniversary of the date of grant, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| December 05, 2017 Filed Dec 6, 2017 23:29 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 29,625 | $1.08 | $32,128.31 |
DisclosureSEC source: 0001493152-17-014280 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,760,784 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 29,625 shares of Issuer common stock on December 5, 2017. Accordingly, Reporting Person beneficially owned 4,760,784 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 21:57 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 45,000 | $1.07 | $48,298.50 |
DisclosureSEC source: 0001493152-17-013958 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,790,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 45,000 shares of Issuer common stock on November 28, 2017. Accordingly, Reporting Person beneficially owned 4,790,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| November 21, 2017 Filed Nov 29, 2017 21:55 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 45,000 | $1.21 | $54,468.00 |
DisclosureSEC source: 0001493152-17-013956 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,835,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 45,000 shares of Issuer common stock on November 21, 2017. Accordingly, Reporting Person beneficially owned 4,835,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 16:54 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 25,000 | $1.13 | $28,295.00 |
DisclosureSEC source: 0001493152-17-012078 · form4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,880,399 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 50,000 shares of Issuer common stock on October 24, 2017. Accordingly, Reporting Person beneficially owned 4,880,399 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 16:54 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 25,000 | $1.14 | $28,455.00 |
DisclosureSEC source: 0001493152-17-012078 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,880,399 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 50,000 shares of Issuer common stock on October 24, 2017. Accordingly, Reporting Person beneficially owned 4,880,399 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 17, 2017 Filed Oct 25, 2017 19:54 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 25,000 | $1.16 | $28,917.50 |
DisclosureSEC source: 0001493152-17-012045 · form4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,930,399 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 50,000 shares of Issuer common stock on October 17, 2017. Accordingly, Reporting Person beneficially owned 4,930,399 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 17, 2017 Filed Oct 25, 2017 19:54 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 25,000 | $1.17 | $29,217.50 |
DisclosureSEC source: 0001493152-17-012045 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,930,399 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 50,000 shares of Issuer common stock on October 17, 2017. Accordingly, Reporting Person beneficially owned 4,930,399 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 10, 2017 Filed Oct 11, 2017 22:26 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 25,000 | $1.39 | $34,727.50 |
DisclosureSEC source: 0001493152-17-011518 · form4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. (2 Disclosed balance after: 5,020,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 50,000 shares of Issuer common stock on October 10, 2017. Accordingly, Reporting Person beneficially owned 5,020,409 shares of Issuer common stock following the reported transactions. Read SEC document |
| October 10, 2017 Filed Oct 11, 2017 22:26 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 25,000 | $1.37 | $34,177.50 |
DisclosureSEC source: 0001493152-17-011518 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,020,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 50,000 shares of Issuer common stock on October 10, 2017. Accordingly, Reporting Person beneficially owned 5,020,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 05, 2017 Filed Oct 10, 2017 22:17 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 22,000 | $1.49 | $32,797.60 |
DisclosureSEC source: 0001493152-17-011463 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,070,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 22,000 shares of Issuer common stock on October 5, 2017. Accordingly, Reporting Person beneficially owned 5,070,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 18:06 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 3,000 | $1.48 | $4,440.00 |
DisclosureSEC source: 0001493152-17-011297 · form4.xml · nonDerivative · entry 3 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,092,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 53,000 shares of Issuer common stock on October 3, 2017 and October 4, 2017. Accordingly, Reporting Person beneficially owned 5,092,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 18:06 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 25,000 | $1.17 | $29,337.50 |
DisclosureSEC source: 0001493152-17-011297 · form4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,092,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 53,000 shares of Issuer common stock on October 3, 2017 and October 4, 2017. Accordingly, Reporting Person beneficially owned 5,092,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 18:06 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 25,000 | $1.19 | $29,707.50 |
DisclosureSEC source: 0001493152-17-011297 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,092,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 53,000 shares of Issuer common stock on October 3, 2017 and October 4, 2017. Accordingly, Reporting Person beneficially owned 5,092,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 16:53 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 25,000 | $1.23 | $30,682.50 |
DisclosureSEC source: 0001493152-17-011018 · form4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,145,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 50,000 shares of Issuer common stock on September 26, 2017. Accordingly, Reporting Person beneficially owned 5,145,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 16:53 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 25,000 | $1.25 | $31,217.50 |
DisclosureSEC source: 0001493152-17-011018 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,145,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 50,000 shares of Issuer common stock on September 26, 2017. Accordingly, Reporting Person beneficially owned 5,145,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| September 19, 2017 Filed Sep 20, 2017 15:42 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 25,000 | $1.18 | $29,380.00 |
DisclosureSEC source: 0001493152-17-010767 · form4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,195,409 F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| September 19, 2017 Filed Sep 20, 2017 15:42 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 25,000 | $1.19 | $29,852.50 |
DisclosureSEC source: 0001493152-17-010767 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,220,409 F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 19:38 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 20,000 | $1.12 | $22,400.00 |
DisclosureSEC source: 0001493152-17-010597 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,204,799 F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| September 06, 2017 Filed Sep 7, 2017 23:22 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 20,000 | $1.01 | $20,200.00 |
DisclosureSEC source: 0001493152-17-010332 · form-4.xml · nonDerivative · entry 3 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,224,799 F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| September 06, 2017 Filed Sep 7, 2017 23:22 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 610 | $1.08 | $658.80 |
DisclosureSEC source: 0001493152-17-010332 · form-4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,244,799 F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| September 06, 2017 Filed Sep 7, 2017 23:22 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 25,000 | $1.00 | $25,000.00 |
DisclosureSEC source: 0001493152-17-010332 · form-4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,245,409 F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| August 30, 2017 Filed Sep 7, 2017 23:20 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 5,000 | $1.06 | $5,302.50 |
DisclosureSEC source: 0001493152-17-010331 · form4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,270,409 F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| August 30, 2017 Filed Sep 7, 2017 23:20 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 5,000 | $1.07 | $5,350.00 |
DisclosureSEC source: 0001493152-17-010331 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,275,409 F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| August 25, 2017 Filed Sep 7, 2017 23:17 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 15,000 | $1.08 | $16,212.00 |
DisclosureSEC source: 0001493152-17-010330 · form4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,280,409 F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| August 24, 2017 Filed Sep 7, 2017 23:17 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 10,000 | $1.03 | $10,311.00 |
DisclosureSEC source: 0001493152-17-010330 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,295,409 F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.